# Celcuity Inc. (CELC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $95.70, market value $4.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Celcuity Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -4.1%** (5-yr avg -12.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -176.1%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -33.9%**. Earnings per share fell 33.9%.

## Financial health
- **Debt to equity: 1.37**. Debt is 1.37 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Celcuity Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Celcuity Inc.; the consensus is strong_buy, with an average price target of $161.09 (+68% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 75.7%** (YTD -4.1%, 3-mo 8.4%). The shares are up 75.7% over twelve months including dividends.
- **From 52-week high: -36.6%** (115.4% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 1.31** (volatility 76%). Beta of 1.31 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CELC · Page: https://foliofundamentals.com/stocks/celc

Not investment advice.